Drugs / HSK31679
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06258746 | Dec 2023 | — | Xizang Haisco Pharmaceutical Co., Ltd | Unknown | No outcome recorded |
| Phase 1 | NCT05531097 | Feb → Sep 2022 | low density lipoprotein cholesterol, mild elevation of | Haisco Pharmaceutical Group Co., Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06168383 | Jan 2024 → Dec 2025 | metabolic dysfunction-associated steatohepatitis | Haisco Pharmaceutical Group Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT05795517 | Apr 2023 → Feb 2024 | hyperlipidemia | Haisco Pharmaceutical Group Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07581951 | Jun 2026 → Jun 2029 expected | NAFLD1, metabolic dysfunction-associated steatohepatitis | Haisco Pharmaceutical Group Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HSK31679 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06168383 ↗ |
| Action | Activate | “the thyroid hormone receptor β agonist HSK31679” PMID 40846146 ↗ Aug 2025 |
| Route | Oral | “Single or multiple oral doses of HSK31679” NCT05531097 ↗ |